All In Biotech

Drug Trial Radar · NCT05138796

A Pharmacokinetic Study of TP-05 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending-Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

May 6, 2021

Primary completion

Mar 25, 2022

Study completion Jul 25, 2022

Sponsor

Lead sponsor
Tarsus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

Conditions

  • Healthy

Interventions

  • TP-05 (lotilaner oral capsules)Drug

    TP-05 (lotilaner oral capsules)

  • PlaceboDrug

    Placebo to match TP-05 (lotilaner oral capsules)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAEs)Time frame: up to 151 days
  2. Clinically significant changes from Baseline chemistry laboratory testsTime frame: up to 151 days
  3. Clinically significant changes from Baseline hematology laboratory testsTime frame: up to 151 days
  4. Clinically significant changes from Baseline general appearanceTime frame: up to 151 days
  5. Clinically significant changes from Baseline physical examination of head, ears, nose, and throatTime frame: up to 151 days
  6. Clinically significant changes from Baseline physical examination of neck (thyroid)Time frame: up to 151 days
  7. Clinically significant changes from Baseline physical examination of respiratory systemTime frame: up to 151 days
  8. Clinically significant changes from Baseline physical examination of cardiovascular systemTime frame: up to 151 days
  9. Clinically significant changes from Baseline physical examination of gastrointestinal systemTime frame: up to 151 days
  10. Clinically significant changes from Baseline physical examination of neurological systemTime frame: up to 151 days
  11. Clinically significant changes from Baseline physical examination of musculoskeletal system (extremities)Time frame: up to 151 days
  12. Clinically significant changes from Baseline physical examination of skinTime frame: up to 151 days
  13. Clinically significant changes from Baseline vital signsTime frame: up to 151 days
  14. Clinically significant changes from Baseline vital signs (temperature [degrees Celsius])Time frame: up to 151 days
  15. Clinically significant changes from Baseline vital signs (pulse rate [beats per minute])Time frame: up to 151 days
  16. Clinically significant changes from Baseline vital signs (respiration rate [breaths per minute])Time frame: up to 151 days
  17. Clinically significant changes from Baseline vital signs (systolic and diastolic blood pressure [mmHg])Time frame: up to 151 days
  18. Clinically significant changes from Baseline electrocardiograms (ECGs)Time frame: up to 151 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.